Tagged abbvie

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron's Dupixent
Press Release

Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron's Dupixent

 Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer's PF-0496582, AbbVie's upadacitinib and Incyte's topical ruxolitinib have the most potential upside if approved Read More
Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis' Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer's Xeljanz
Press Release

Ankylosing Spondylitis Market Largely Dominated by TNF-Inhibitors, Though Novartis' Cosentyx Enjoyed Significant Year Over Year Gains and a Growing Percent of Rheumatologists Report Off-Label Use of Pfizer's Xeljanz

 With no current FDA approved biologics for the treatment of non-radiographic axial spondyloarthropathy, overall penetration of biologics/JAKs is significantly lower than for ankylosing spondylitis; however, when these agents are prescribed, brand usage closely mirrors the ankylosing spondylitis indication, according to a new publication by Spherix Global Insights Read More
Press Release

Pfizer's Xeljanz Begins to Shift the Treatment Paradigm in Ulcerative Colitis (UC) With Early Launch Metrics Largely Favorable for the Brand

 The majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights Read More
Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation
Press Release

Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation

 Read More
Press Release

Next Generation HCV Therapy Presented at the International Liver Congress™ 2017 by Texas Liver Institute's Dr. Fred Poordad

 Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies Read More